Pemirolast sodium

Drug Profile

Pemirolast sodium

Alternative Names: CRD 007

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Cardoz
  • Developer Cardoz; RSPR Pharma
  • Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma
  • No development reported Vasculitis

Most Recent Events

  • 13 May 2016 Efficacy data from a phase II trial in Asthma presented at the Conference of the American Thoracic Society (ATS-2016)
  • 01 Nov 2015 Phase-II clinical trials in Asthma (Adjunctive treatment) in Denmark (PO)
  • 20 Jul 2015 No recent reports of development identified - Phase-II for Vasculitis in Denmark, Sweden, United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top